TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Celgene Makes $9 Billion Cancer Treatment Play for Juno Therapeutics
OPINION

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

  • By Michael Brown
  • Jan 22, 2018 7:23 PM EST
PRESS RELEASES

Cellectis And Servier Execute The Amendment Confirming The Expansion Of Their Collaboration On UCART19 Products

  • By Business Wire
  • Mar 4, 2020 4:05 PM EST
PRESS RELEASES

Cellectis To Hold Fourth Quarter And Full Year 2019 Earnings Call On Thursday, March 5, 2020 At 7:30 AM EST

  • By Business Wire
  • Feb 25, 2020 4:30 PM EST
PRESS RELEASES

Cellectis And Servier Expand Collaboration On UCART19 Products

  • By Business Wire
  • Feb 18, 2020 4:30 PM EST
PRESS RELEASES

First Patient Dosed With Cellectis' New Allogeneic UCART123 Product Candidate For Relapsed/Refractory Acute Myeloid Leukemia

  • By Business Wire
  • Jan 15, 2020 4:30 PM EST
Celgene Makes $9 Billion Cancer Treatment Play for Juno Therapeutics
OPINION

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

  • By Michael Brown
  • Jan 22, 2018 7:23 PM EST
Immunotherapy Stocks Power Higher on Celgene-Juno Deal
STOCKS

Immunotherapy stocks power higher on Celgene-Juno deal

  • By Armie Margaret Lee
  • Jan 22, 2018 12:03 PM EST
Gene Editing Company Joins NASDAQ, Jumps Over 20% on First Day
HEALTH

Gene Editing Company Joins NASDAQ, Jumps Over 20% on First Day

  • By Melissa Angell
  • Jul 21, 2017 12:26 PM EDT
YogaWorks Is Betting on Millennial Interest in the Ancient Practice, Ahead of Its IPO on Thursday
STOCKS

Tired of hearing about Blue Apron's fall? Check out the next wave of talked about IPOs

  • By Michael Brown
  • Jul 17, 2017 12:12 PM EDT
Bunge Stock Rises After It Hires JPMorgan and Shearman & Sterling to Defend Against Takeover Bid
HEALTH

Move Over GMO's: IPO for Gene Editor Calyxt Launches Next Week

  • By Melissa Angell
  • Jul 10, 2017 5:09 PM EDT
Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment
STOCKS

Cellectis gains FDA nod to test new gene-edited cancer treatment

  • By Gregg Greenberg
  • Feb 7, 2017 12:27 PM EST
Cellectis Gets FDA Nod to Test New Gene-Edited Cancer Treatment
VIDEO

Cellectis Gets FDA Nod to Test New Gene-Edited Cancer Treatment

  • By Gregg Greenberg
  • Feb 7, 2017 12:14 PM EST
Valeant Acquires Eyegate Licensing Rights
OPINION

13 companies to watch from MIT's smart 50 list, including 4 buys

  • By Robert Wasserman
  • Jul 21, 2016 7:48 AM EDT
Today's Weak On High Volume Stock: Spirit AeroSystems Holdings (SPR)
MARKETS

Trade-Ideas: Cellectis (CLLS) Is Today's Weak On High Relative Volume Stock

  • By TheStreet Wire
  • Jul 8, 2016 10:33 AM EDT
CEOs Should Set Tone for Corporate Culture
VIDEO

CEOs Should Set Tone for Corporate Culture

  • By Rhonda Schaffler
  • Jun 16, 2016 11:19 AM EDT
Activist Fund Hudson Executive Capital is About To Make Another Investment
OPINION

Managing corporate governance easier said than done

  • By Emily Stewart
  • Jun 6, 2016 5:11 PM EDT
Chiasma's Acromegaly Drug Headed for FDA Rejection, Investor Says
STOCKS

Juno, Kite valuations at risk from simpler T-Cell cancer therapy

  • By Adam Feuerstein
  • Jan 26, 2016 11:15 AM EST
Jim Cramer's Top Takeaways: Norfolk Southern, Caterpillar, Smith & Wesson
OPINION

Jim cramer's top takeaways: paychex and cellectis

  • By Scott Rutt
  • Dec 23, 2015 6:00 AM EST
Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
JIM CRAMER

Jim Cramer's 'Mad Money' Recap: Welcome to Crazy Town

  • By Scott Rutt
  • Dec 22, 2015 8:09 PM EST
Amicus Shares Barely Budge on Prediction of $3 Billion Buyout
STOCKS

Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data

  • By Adam Feuerstein
  • Nov 5, 2015 11:21 AM EST
TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL
INVESTING

Before the Move: Watch Cellectis Into UCART19 Data

  • By The Fly Staff
  • Nov 2, 2015 3:10 PM EST
5 Best-Positioned Biotech Stocks on Brexit Volatility
INVESTING

Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector

  • By The Fly Staff
  • Oct 5, 2015 10:53 AM EDT
Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs
INVESTING

Biotech Selloff Has No Effect on Cellectis Advances: CEO

  • By Gregg Greenberg
  • Aug 26, 2015 11:29 AM EDT
Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO
VIDEO

Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO

  • By Gregg Greenberg
  • Aug 26, 2015 11:05 AM EDT
Textron (TXT) Stock Climbs on Q1 Earnings Beat
OPINION

5 Stocks Ready for Breakouts

  • By Roberto Pedone
  • Aug 7, 2015 9:29 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.